Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. IRT
8. QCOM
9. AEO
10. MSI

Go back to Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Myriad Genetics, Inc. (NASDAQ: MYGN) Delayed: 3.19 +0.01 (0.31%)
Previous Close $3.18    52 Week High $45.34 
Open $3.11    52 Week Low $15.92 
Day High $3.22    P/E 1.37 
Day Low $3.09    EPS $2.33 
Volume 966,999